Recent events
Recent events tied to this brand in public sources.
Back to profile37 entries · Page 1 of 2
2026
Abbott announces planned nutrition business spin-off
Abbott announced plans to spin off its global nutrition business as a separately listed company. The business, which includes Similac, PediaSure, Pedialyte, Glucerna and Ensure, is expected to complete the transaction by the end of 2027.
2026
Abbott announces a baby formula spinoff
Abbott Laboratories announced a baby formula spinoff company.
2026
Abbott cuts its 2026 sales growth forecast
Abbott cut its 2026 sales growth forecast to about 6%, from its previous expectation of 6.5% to 7.5%.
2022
Parent sues Abbott over alleged infant formula injuries
A parent filed a complaint against Abbott Laboratories alleging that Abbott cow’s-milk-based formula and/or fortifier caused a premature infant to develop NEC and that the products were misleadingly marketed and inadequately warned about potential risks. These are allegations in the complaint, not a court determination.
2022
Abbott recalls a lot of Similac PM 60/40 formula
Abbott Laboratories issued a second round of baby formula recalls on February 28, 2022, covering one lot of Similac PM 60/40. The article says the recall followed the company learning that an infant who consumed the formula had died after contracting a Cronobacter sakazakii infection; it does not establish that the formula caused the death.
2022
Abbott recalls six lots of Similac Alimentum in Vietnam
Abbott Laboratories GmbH’s Hanoi representative office announced a voluntary recall in Vietnam of six lots of Similac Alimentum Eye-Q powdered infant formula because they potentially contained two kinds of dangerous bacteria. The article reports that 7,050 cartons had entered the market and that the importer notified customers about the recall.
2022
Abbott recalls three infant formula products
Abbott recalled three infant formula products after Cronobacter sakazakii was found in a non-product-contact area of a Michigan factory; the source says the products could pose a health risk to infants aged 0–6 months and that the investigation was ongoing.
2022
Vietnam orders recall of certain Abbott formula products
Vietnam's Food Safety Authority issued a recall of certain potentially contaminated food products sold by Abbott after reports of contamination incidents in the U.S. The agency contacted importers and asked them to recall the products.
2022
Abbott recalls potentially affected powdered infant formulas
Abbott said it was recalling potentially affected products manufactured at its Sturgis, Michigan facility after reports of infant illnesses linked to bacterial contamination. The recall affected certain products with expiration dates of April 1, 2022, or later. Abbott expressed regret for the concern and inconvenience the situation would cause.
2022
Abbott announces recall of three infant-formula product lines
Abbott announced a voluntary recall of Similac, Alimentum and EleCare formula produced at its Sturgis, Michigan factory. The article identifies affected product codes and expiration dates.
2021
Lawsuit filed against formula manufacturers over alleged NEC-related injuries
A plaintiff filed suit against Abbott Laboratories, Inc., Mead Johnson & Company, LLC, and Mead Johnson Nutrition Company, alleging that their cow’s-milk-based products caused an infant’s injuries and asserting failure-to-warn, defective-product, and negligence claims. These are allegations in the complaint.
2021
Lawsuit filed against Abbott over infant formula
A parent filed a product-liability lawsuit against Abbott Laboratories concerning cow’s milk-based infant formula fed to a premature baby. The plaintiff alleges that the product was falsely marketed as being as safe as breast milk and asserts claims including design defect, failure to warn, and negligence.
2021
FDA approves Abbott Portico with FlexNav TAVR system
The US Food and Drug Administration approved Abbott's Portico with FlexNav transcatheter aortic valve replacement system for certain patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
2021
Abbott's Shanghai entity fined over advertising violations
The Shanghai Municipal Administration for Market Regulation fined Abbott Trading (Shanghai) Co., Ltd. RMB 848,000 and ordered it to stop publishing advertisements for medical services, medicines and medical devices that violated regulations.
2021
Abbott launches implantable device for babies with PDA
Abbott launched a medical device that it claims is the world’s first implantable device for treating patent ductus arteriosus in babies weighing as little as 700 grams, using a minimally invasive procedure.
2021
Abbott ends operations at Gurnee test assembly plant
Abbott ended operations at its Gurnee, Illinois assembly plant, where workers had been manufacturing BinaxNOW COVID-19 tests. Workers were told on Tuesday they no longer needed to report to work.
2021
Shanghai regulator fines Abbott trading subsidiary over contaminated food products
Shanghai's market regulator imposed an administrative penalty on Abbott Trading (Shanghai) Co., Ltd., including a fine of 9,093,140.58 yuan, over the production and sale of food allegedly contaminated by packaging materials, containers, or transport tools.
2021
Abbott launches NeuroSphere Virtual Clinic in the U.S.
Abbott announced the U.S. launch of NeuroSphere Virtual Clinic, a technology that lets patients communicate with physicians and receive neurostimulation treatment settings remotely.
2021
Abbott wins U.S. Secretary of State’s Award for Innovation in Rwanda
Abbott won the 2020 U.S. Secretary of State’s Award for Corporate Excellence in the Innovation category for its work expanding preventative health care in underserved rural areas of Rwanda.
2021
Abbott makes BinaxNOW available to schools and workplaces
Abbott announced that its BinaxNOW COVID-19 rapid antigen test was being made available to schools, universities, pharmacies, and workplaces requiring frequent and affordable testing.